
Table of Contents

1. SUMMARY	8
2. ABBREVIATIONS	13
3. INTRODUCTION AND THE OBJECTIVES OF THE STUDY	17
4. DRUG DISCOVERY AND RATIONAL DRUG DESIGN	20
4.1. INTRODUCTION TO DRUG DISCOVERY	20
4.1.1. Drug discovery process.....	21
4.1.1.1. Target identification	21
4.1.1.2. Target validation	23
4.1.1.3. Lead identification:.....	23
4.1.1.4. Lead optimization:.....	25
4.1.1.5. Preclinical and clinical development:.....	26
4.2. RATIONAL DRUG DESIGN	27
4.2.1. Computer-assisted drug Design (CADD).....	29
4.2.1.1. Ligand-Based Drug Design (LBDD).....	30
4.2.1.2. Structure-Based-Drug Design (SBDD).....	31
4.2.1.3. Docking and scoring.....	35
4.2.1.4. Virtual screening (VS), High throughput virtual screening (HTVS)	45
5. MYELOPEROXIDASE AS A TARGET FOR DRUG DISCOVERY	55
5.1. MPO ROLE IN INFLAMMATION AND INFLAMMATORY DISEASES	56
5.2. MPO AND CARDIOVASCULAR DISEASES.....	58
5.3. MPO ROLE IN THE NEURODEGENERATIVE DISEASES	60
5.4. MPO ROLE IN RENAL DISEASES.....	60
5.5. MPO ROLE IN CANCER DISEASES	61
5.6.1. Introduction to X-ray Crystallography	62
5.6.2. MPO structure and its Crystallography data.....	66
5.6.2.1. The first published X-ray structures of MPO (1992-1995, Fenna and Zeng work).	72
5.6.2.2. The X-ray structures of MPO with Cl ⁻ , Br ⁻ , CN ⁻ , SCN ⁻ ligands	73
5.6.2.3. The x-ray structure of MPO and the proximal histidine (His336) orientation	76
5.6.2.4. The X-ray structure of MPO inactivated by thioxanthine derivatives and Ceruloplasmin.	78
5.6.2.5. The X-ray structure of MPO complexed with aromatic hydroxamates.....	82
5.6.2.6. The X-ray structure of MPO of the highest resolution (5FIW).....	84
5.6.2.7. Comments on MPO structure:	84
5.7. MECHANISM OF ACTION OF MPO	86
5.8. INHIBITION OF MPO ACTIVITY	90
5.9. MPO INHIBITORS.....	91
5.9.1. Random screening: tests and MPO inhibitors.....	91
5.9.1.1. Screening tests.....	91
5.9.1.2. Random screenings	95
5.9.1.2.1. Natural compounds	95
5.9.1.2.1.1. Flavonoids, Polyphenols and Chalcones	95
5.9.1.2.1.2. Indole derivatives	98
5.9.1.2.2. Commercial drugs as MPO inhibitors.....	98

5.9.2. Pharmacomodulation approaches of hits that inhibit MPO	99
5.9.2.1. Benzoic acid hydrazide	99
5.9.2.2. Aromatic hydroxamic acids.....	100
5.9.2.3. Flufenamic acid derivatives.....	102
5.9.2.4. Tryptamine derivatives.....	103
5.9.2.5. Indazole and indazolone derivatives	104
5.9.2.6. Naphthalene derivatives	105
5.9.2.7. Nitroxide derivatives.....	106
5.9.2.8. Thioxanthines, 2-Thiopyrimidinone, 2- Thio-2,3-dihydroquinazolin-4-one derivatives	106
5.10. DOCKING AND HTVS APPROACHES FOR FINDING MPO INHIBITORS.....	109
6. MATERIALS AND METHODS	115
6.1. MATERIALS AND METHODS USED IN SYNTHESIS AND DOCKING.	115
6.2. <i>IN VITRO</i> BIOLOGICAL TESTS.....	118
7. RESULTS AND DISCUSSION	123
7.1. EVALUATION OF NEW SCAFFOLDS OF MYELOPEROXIDASE INHIBITORS BY RATIONAL DESIGN COMBINED WITH HIGH-THROUGHPUT VIRTUAL SCREENING	123
7.1.1. Introduction	123
7.1.2. Results	124
7.1.2.1. <i>In vitro</i> tests and best docking experiments poses of the best MPO inhibitors	125
7.1.3. Discussion and Conclusion.....	131
7.2. NOVEL BIS-ARYLALKYLAMINES AS MYELOPEROXIDASE INHIBITORS: DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIP STUDY	144
7.2.1. Introduction	144
7.2.2. Results	145
7.2.2.1. Docking experiments.....	145
7.2.2.2 Chemistry.	156
7.2.2.3 Inhibition of chlorination activity of myeloperoxidase.....	158
7.2.2.3 Transient-state kinetics between MPO compound I and compound II with inhibitors	158
7.2.2.4 Serotonin reuptake inhibition, electron density maps and determination of redox potentials	159
7.2.3. Discussion and Conclusion.....	159
8. FUTURE WORK	179
9. APPENDIXES	180
9.1. SYNTHESIS PROCEDURES	180
10. BIBLIOGRAPHY	222